Abstract: The present invention relates to a genetically modified plant having an increased amount of oil in its green biomass as compared to the oil in the green biomass of its non-genetically modified counterpart. The plants may be used for producing bio-fuels such as biodiesel fuel.

Abstract: The present invention relates to a genetically modified plant having an increased amount of oil in its green biomass as compared to the oil in the green biomass of its non-genetically modified counterpart. The plants may be used for producing bio-fuels such as biodiesel fuel.

Abstract: Methods of in vitro propagation of plants of the genus Eriodictyon are described, including, in particular embodiments, plants of the species E. californicum, E. trichocalyx and E. sessilifolium. Methods of producing transgenic plants of the genus Eriodictyon are also described, along with methods of producing recombinant proteins in such plants. Compositions and methods for administering recombinant proteins produced in these plants are also described.

Abstract: Methods of in vitro propagation of plants of the genus Eriodictyon are described, including, in particular embodiments, plants of the species E. californicum, E. trichocalyx and E. sessilifolium. Methods of producing transgenic plants of the genus Eriodictyon are also described, along with methods of producing recombinant proteins in such plants. Compositions and methods for administering recombinant proteins produced in these plants are also described.

Abstract: The present invention relates to a genetically modified plant having an increased amount of oil in its green biomass as compared to the oil in the green biomass of its non-genetically modified counterpart. The plants may be used for producing bio-fuels such as biodiesel fuel.

Abstract: Methods of in vitro propagation of plants of the genus Eriodictyon are described, including, in particular embodiments, plants of the species E. californicum, E. trichocalyx and E. sessilifolium. Methods of producing transgenic plants of the genus Eriodictyon are also described, along with methods of producing recombinant proteins in such plants. Compositions and methods for administering recombinant proteins produced in these plants are also described.

Abstract: The present invention relates to a method for the generation of transgenic Brassica oleracea plants, in particular transgenic Cruciferae (also known as Brassicaceae) plants. The present invention also provides a method for the production of heterologous proteins using a Cruciferae-based plant system, for example pharmaceutical and/or recombinant proteins. In particular the invention also relates to a method for the production of transgenic collard and cauliflower, and to the large scale production of pharmaceutical and/or therapeutic production, such as production of Cruciferae-based vaccine production.

Abstract: The invention as described herein provides compositions and methods for cancer immunotherapy and cancer detection. In particular, the invention discloses plant-derived human monoclonal antibodies that bind human carcinoma antigens in cancer cell lines.

Abstract: Human rabies monoclonal antibodies (rabies MAbP) comprising rabies human MAb S057 heavy chain and light chain subunits are expressed and assembled in plants under the control of two strong constitutive promoters. Additionally, regulatory control elements such as alfalfa mosaic virus untranslated leader sequence and Lys-Asp-Glu-Leu (KDEL) endoplasmic reticulum retention signal were linked at the N- and C-terminus of the heavy chain of human rabies MAbP, respectively to regulate expression of the rabies MAbP. Rabies MAbP was as effective at neutralizing the activity of the rabies virus as the mammalian-derived antibody (MAbM) or human rabies immunoglobulin (HRIG).

Abstract: The present invention discloses novel methods for producing foreign polypeptides in a host plant using recombinant viruses through functional complementation systems. The methods involve constructing suitable recombinant viral vectors that are capable of systemic infection and infecting the host plants with one or more recombinant viral vectors. The methods are also directed to infecting a host plant that is transgenic for expressing replicase genes of a virus, wherein the transgenic plant expressing a virus replicase genes complements the virus replicase function. The invention also discloses a method for producing a full-length antibody in a host plant using viral vectors.

Abstract: The invention as described herein provides compositions and methods for cancer immunotherapy and cancer detection. In particular, the invention discloses plant-derived human monoclonal antibodies that bind human carcinoma antigens in cancer cell lines.

Abstract: The present invention describes novel soluble variants of type I membrane protein GA733-2 and methods of making and using them. In addition, the present invention describes a method of converting type I membrane proteins into secretory proteins which may be used for active immunotherapy against carcinomas and as reagents in the detection of GA733-2 expression on tumor cells.

Abstract: The present invention describes novel soluble variants of type I membrane protein GA733-2 and methods of making and using them. In addition, the present invention describes a method of converting type I membrane proteins into secretory proteins which may be used for active immunotherapy against carcinomas and as reagents in the detection of GA733-2 expression on tumor cells.

Abstract: A fusion capsid protein comprising a plant virus capsid protein fused to an antigenic polypeptide is used as a molecule for presentation of that polypeptide to the immune system of an animal such as a human. The plant virus capsid protein is that of an alfalfa mosaic virus (AlMV) or ilarvirus.

Abstract: Chimeric viral proteins and nucleic acid constructs that code for them and are useful as therapeutic agents are disclosed.

Abstract: Chimeric viral proteins and nucleic acid constructs that code for them and are useful as therapeutic agents are disclosed.

Abstract: Oligodeoxynucleotides complementary to genomic RNA of a negative-stranded nonsegmented RNA virus are provided. Methods of inhibiting infection of cells by a negative-stranded nonsegmented RNA virus and treating animals infected with a negative-stranded nonsegmented RNA virus using these oligodeoxynucleotides are also provided.

Abstract: Chimeric viral proteins and nucleic acid constructs that code for them and are useful as therapeutic agents.

Abstract: Methods of enhancing an antigen-induced immune response through use of a ribonucleocapsid complex are provided. Composition containing a ribonucleocapsid complex and an antigen which are capable of enhancing the immune response to the antigen are also provided.

Abstract: A fusion capsid protein comprising a plant virus capsid protein fused to an antigenic polypeptide is used as a molecule for presentation of that polypeptide to the immune system of an animal such as a human. The plant virus capsid protein is that of an alfalfa mosaic virus (AlMV) or ilarvirus.